The Journal of Clinical Endocrinology & Metabolism · 2022 · 18 citations · 32 references
MedicineBiochemistryEndocrinologyDiabetologyGlycobiologyMetabolic RegulationBlood Glucose MonitoringDiabetes MellitusDiabetes Mellitus BiochemistryGlycemic ControlGlycemic MonitoringGlucose Metabolism BiomarkersGlycemic BiomarkersHemoglobin A1c Testing
CONTEXT: During an asymptomatic prediabetic state, the functional ß-cell mass decreases to a critical threshold, triggering diabetes and related symptoms. To date, there are no reliable readouts able to capture in vivo a potential drop of the ß-cell mass. OBJECTIVE: Beside its use as a short-term marker of glycemic control, the deoxyhexose 1,5-anhydroglucitol was identified in rodents as a circulating biomarker of the functional ß-cell mass already in the asymptomatic prediabetic stage. The present study investigated the putative corresponding relevance of circulating 1,5-anhydroglucitol in different human cohorts. METHODS: We analyzed clinical and blood parameters in patients with established type 2 diabetes and subjects considered at high risk of developing diabetes, as well as patients with no history of diabetes scheduled for pancreaticoduodenectomy. RESULTS: Circulating 1,5-anhydroglucitol was reduced in type 2 diabetic patients, negatively correlating with fasting plasma glucose (P < 0.0001) and hemoglobin A1c (P < 0.0001). In healthy subjects, 1,5-AG levels positively correlated with body mass index (P = 0.004) and Homeostatic Model Assessment of Insulin Resistance %S (P < 0.03) and was particularly high in nondiabetic obese individuals, potentially accounting for compensatory ß-cell expansion. Patients with no history of diabetes undergoing pancreaticoduodenectomy exhibited a 50% reduction of circulating 1,5-anhydroglucitol levels following surgery leading to an acute loss of their ß-cell mass (P = 0.002), regardless their glucose tolerance status. CONCLUSION: In summary, plasma concentration of 1,5-anhydroglucitol follows the ß-cell mass and its noninvasive monitoring may alert about the loss of ß cells in subjects at risk for diabetes, an event that cannot be captured by other clinical parameters of glycemic control.
32
Standards of Medical Care in Diabetes—2013
Diabetes Care · 2012 · 4.4K citations · Full text
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Alexandra E. Butler, Juliette Janson, Susan Bonner‐Weir et al. · Diabetes · 2003 · 4K citations
Medicine, Endocrinology, Physiology +17
A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test
Andrea Mari, Giovanni Pacini, Elaine Murphy et al. · Diabetes Care · 2001 · 803 citations · Full text